PCRX — Pacira Biosciences Balance Sheet
0.000.00%
- $1.02bn
- $1.15bn
- $700.97m
- 94
- 76
- 76
- 96
Annual balance sheet for Pacira Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 522 | 656 | 289 | 279 | 485 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 53 | 96.3 | 98.4 | 106 | 113 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 652 | 866 | 498 | 510 | 745 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 211 | 265 | 254 | 235 | 216 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,275 | 2,075 | 1,681 | 1,574 | 1,554 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 253 | 521 | 148 | 97.4 | 310 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 655 | 1,345 | 906 | 704 | 775 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 620 | 730 | 775 | 870 | 778 |
| Total Liabilities & Shareholders' Equity | 1,275 | 2,075 | 1,681 | 1,574 | 1,554 |
| Total Common Shares Outstanding |